Tag ~immunotherapy

Tag descriptions coming soon to Wherrelz News!

geekwire
Biotech startup Kineta inks cancer deal with Pfizer worth up to 505M
geekwire
BristolMyers Squibbs 74B acquisition of Juno parent Celgene puts Seattle biotech world on alert
geekwire
Cell therapies are giving Seattle an edge in biotech driving three acquisitions in under a month
geekwire
Seattle Genetics to acquire Cascadian Therapeutics for 614M to further bolster its cancer fight
techcrunch
The convergence of deep neural networks and immunotherapy
geekwire
Portland immunotherapy startup tops 10M in funding as it launches first clinical trial
rednewswire
CAR TCell Immunotherapy Market Competitive Landscape Trends Market Concentration Rate Business Strategies 2023
geekwire
Juno finds clinical success with cancer drug beats analyst expectations with 44M in revenue
geekwire
OncoResponse raises 40M to start clinical trials of antibodybased cancer immunotherapies
geekwire
Sonoma Biotherapeutics raises 265M to advance therapies for autoimmune inflammatory diseases
feeds.feedburner
Immunai wants to map the entire immune system and raised 20 million in seed funding to do it
geekwire
Fred Hutch study: Nanoparticles could help cuttingedge therapies get inside solid tumors
geekwire
Startup Aminex Therapeutics raises 10M begins clinical trials of immunotherapy treatment
geekwire
Juno Therapeutics stock surges 50 as Celgene is reportedly in talks to buy the company
geekwire
How this cancer therapy went from scientific underdog to potential cure
geekwire
Seattle Genetics COO taking the reins at stealthy biotech startup Silverback Therapeutics
geekwire
Inside Seattle Childrens landmark 1B campaign to cure childhood cancer and other diseases
geekwire
Thin metal films loaded with immune cells show promise as cancer therapy
geekwire
Celgene CEO: Treating cancer is becoming ironically easy now the problem is affordability
geekwire
Why Celgene decided to buy Juno Therapeutics for 9B with a little help from US tax reform
geekwire
Drug giant Merck pays 300M to acquire Seattle biotech company Immune Design
geekwire
Longtime Juno Therapeutics CEO Hans Bishop leaves role after merger with Celgene
geekwire
Longtime Juno Therapeutics CEO Hans Bishop leaves role after acquisition by Celgene
geekwire
Merck research chief Roger Perlmutter touts Seattle biotech strength after 300M Immune Design deal